Cynomolgus CCL21 / SCYA21 Protein (Native) (Cytokine)

Chemokine (C-C motif) ligand 21 Protein Datasheet

CCL21 / SCYA21 Protein Product Information

• Synonym: CCL21
• Protein Construction: A DNA sequence encoding the cyno CCL21 (Q8HYP5) (Met 1-Pro131) was expressed and purified.
• Source: Cynomolgus monkey
• Expression Host: Baculovirus-Insect cells

CCL21 / SCYA21 Protein QC Testing

• Purity: > 94 % as determined by SDS-PAGE
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Ser 24
• Molecular Mass: The recombinant cyno CCL21 consists of 108 amino acids and has a calculated molecular mass of 12 kDa. It migrates as an 16 KDa band in SDS-PAGE under reducing conditions.
• Formulation: Lyophilized from sterile PBS.
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: CCL21 / SCYA21 protein

CCL21 / SCYA21 Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

CCL21 / SCYA21 Protein Description

C-C motif chemokine 21, also known as 6Ckine, Beta-chemokine exodus-2. Secondary lymphoid-tissue chemokine, Small-inducible cytokine A21, CCL21 and SCYA21, is a secreted protein which belongs to the intercrine beta (chemokine CC) family. CCL21 / SCYA21 is highly expressed in high endothelial venules of lymph nodes, spleen and appendix. Intermediate levels of CCL21 / SCYA21 is found in small intestine, thyroid gland and trachea. Low level expression of CCL21 / SCYA21 in thymus, bone marrow, liver, and pancreas. It is also found in tonsil, fetal heart and fetal spleen. CCL21 / SCYA21 inhibits hemopoiesis and stimulates chemotaxis. CCL21 / SCYA21 shows preferential activity towards naive T-cells. It may play a role in mediating homing of lymphocytes to secondary lymphoid organs. CCL21 / SCYA21 has shown biological activities that include T cell, natural killer (NK) cell, and dendritic cell (DC) chemoattraction. Intratumoral administration of CCL21 / SCYA21 has potential as a neoadjuvant mmunotherapy for breast cancer.

References

1. Christopherson KW. et al., 2001, Blood. 98 (13): 3562-8.
2. Clark HF. et al., 2003, Genome Res. 13: 2265-2270.
3. Ashour AE. et al., 2007, Cancer Biol Ther. 6 (8): 1206-10.
4. Mumtaz M. et al., 2009, Oncol Rep. 21 (1): 153-8.